The term 'Osimertinib EPAR', which combines the drug osimertinib with the EMA's (EMA) regulatory authorization procedure, has gained significant attention in the pharmaceutical sector.A precision medicine for pulmonary cancer, osimertinib, has demonstrated remarkable efficacy in treating patients with specific mutations.The aim of this article is to provide a comprehensive overview of Osimertinib EPAR, its significance, and the associated requirements for authorization for market.Also known as Tagrisso, osimertinib is a TKI (TKI) that selectively targets the EGFR (epidermal growth factor receptor) mutation in pulmonary cancer cells.Osimertinib prevents the abnormal mitosis and…
